Table 1.
Characteristics of patients.
| No. Patients | 114 |
|---|---|
| Age, mean [range], years | 63 [19–95] |
| Sex Male (%) Female (%) |
63 (55.3) 51 (44.7) |
| Patients with comorbidities (%) None Cardiovascular disease Hypertension COPD Diabetes Immunosuppression |
29 (25,4%) 59 (51,8%) 56 (49,1%) 17 (14,9%) 25 (21,9%) 17 (14,9%) |
| O2 sat. on admission. while breathing ambient air, mean [range], % | 90,1 [55–99] |
| Clinical presentationa (%) Mild disease Moderate disease Severe disease |
0 (0%) 10 (8,8%) 104 (91,2%) |
| HCQ (%) | 107 (93.8) |
| ECG pretreatment (% of HCQ) | 100 (93.4) |
| QTc initial, mean [range] msec | 429 [342–493] |
| Drug-drug interaction (% of HCQ) Azithromycin Otherb |
34 (31.8) 28 (26.2) 6 (5.6) |
| ECG CTRL at day 2 (% of patient w. drug-drug interaction) Azithromycin Other |
27 (79.4) 24 (70.5) 3 (8.8) |
a
“Mild disease” was define as symptoms of upper respiratory infection (fever, fatigue, myalgia, cough, sore throat, runny nose, sneezing) or digestive symptoms (nausea, vomiting, abdominal pain, diarrhea); “moderate” as clinical (fever and cough) and radiological pneumonia (infiltrates) without hypoxemia; “severe” as clinical and radiological pneumonia with hypoxemia (O2 saturation < 93%).
b
Other consisted in escitalopram, citalopram, fluconazole, valproate, mirtazapine and olanzapine.